Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116


Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.

O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran C, Rani S, O'Driscoll L, Fitzpatrick JM, Watson RW.

Mol Cancer. 2011 Oct 7;10:126. doi: 10.1186/1476-4598-10-126.


Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.

Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B.

Clin Cancer Res. 2006 Sep 15;12(18):5578-86.


Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression.

Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q.

Mol Cancer. 2011 Aug 31;10:106. doi: 10.1186/1476-4598-10-106.


Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.

Kim SM, Lee SY, Cho JS, Son SM, Choi SS, Yun YP, Yoo HS, Yoon DY, Oh KW, Han SB, Hong JT.

Eur J Pharmacol. 2010 Apr 10;631(1-3):1-9. doi: 10.1016/j.ejphar.2009.12.018. Epub 2010 Jan 6.


Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel.

Desarnaud F, Geck P, Parkin C, Carpinito G, Makarovskiy AN.

Cancer Biol Ther. 2011 Jan 15;11(2):204-12. Epub 2011 Jan 15.


Identification of docetaxel resistance genes in castration-resistant prostate cancer.

Marín-Aguilera M, Codony-Servat J, Kalko SG, Fernández PL, Bermudo R, Buxo E, Ribal MJ, Gascón P, Mellado B.

Mol Cancer Ther. 2012 Feb;11(2):329-39. doi: 10.1158/1535-7163.MCT-11-0289. Epub 2011 Oct 25.


Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.

Marín-Aguilera M, Codony-Servat J, Reig Ò, Lozano JJ, Fernández PL, Pereira MV, Jiménez N, Donovan M, Puig P, Mengual L, Bermudo R, Font A, Gallardo E, Ribal MJ, Alcaraz A, Gascón P, Mellado B.

Mol Cancer Ther. 2014 May;13(5):1270-84. doi: 10.1158/1535-7163.MCT-13-0775. Epub 2014 Mar 21.


Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.

Codony-Servat J, Marín-Aguilera M, Visa L, García-Albéniz X, Pineda E, Fernández PL, Filella X, Gascón P, Mellado B.

Prostate. 2013 Apr;73(5):512-21. doi: 10.1002/pros.22591. Epub 2012 Oct 4.


Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-kappaB.

Lee SY, Cho JS, Yuk DY, Moon DC, Jung JK, Yoo HS, Lee YM, Han SB, Oh KW, Hong JT.

J Pharmacol Sci. 2009 Oct;111(2):124-36.


NF-kappaB activation enhances cell death by antimitotic drugs in human prostate cancer cells.

Parrondo R, de las Pozas A, Reiner T, Rai P, Perez-Stable C.

Mol Cancer. 2010 Jul 9;9:182. doi: 10.1186/1476-4598-9-182.


Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer.

Song L, Xiong H, Li J, Liao W, Wang L, Wu J, Li M.

Clin Cancer Res. 2011 Apr 1;17(7):1839-49. doi: 10.1158/1078-0432.CCR-10-0720. Epub 2011 Feb 15.


γ-tocotrienol enhances the chemosensitivity of human oral cancer cells to docetaxel through the downregulation of the expression of NF-κB-regulated anti-apoptotic gene products.

Kani K, Momota Y, Harada M, Yamamura Y, Aota K, Yamanoi T, Takano H, Motegi K, Azuma M.

Int J Oncol. 2013 Jan;42(1):75-82. doi: 10.3892/ijo.2012.1692. Epub 2012 Nov 8.


Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells.

Sprowl JA, Reed K, Armstrong SR, Lanner C, Guo B, Kalatskaya I, Stein L, Hembruff SL, Tam A, Parissenti AM.

Breast Cancer Res. 2012 Jan 6;14(1):R2.


Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells.

Zhang Y, Wang Y, Yuan J, Qin W, Liu F, Wang F, Zhang G, Yang X.

Cell Biol Toxicol. 2012 Aug;28(4):269-77. doi: 10.1007/s10565-012-9221-2. Epub 2012 Jun 1.


CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.

Qian DZ, Rademacher BL, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS, Beer TM.

Prostate. 2010 Mar 1;70(4):433-42. doi: 10.1002/pros.21077.


Enhancement of TPA-induced growth inhibition and apoptosis in myeloid leukemia cells by BAY 11-7082, an NF-kappaB inhibitor.

Hansson A, Marín YE, Suh J, Rabson AB, Chen S, Huberman E, Chang RL, Conney AH, Zheng X.

Int J Oncol. 2005 Oct;27(4):941-8.


Contributions of mitogen-activated protein kinase and nuclear factor kappa B to N-(4-hydroxyphenyl)retinamide-induced apoptosis in prostate cancer cells.

Shimada K, Nakamura M, Ishida E, Kishi M, Yonehara S, Konishi N.

Mol Carcinog. 2002 Nov;35(3):127-37.


miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.

Wang Y, Lieberman R, Pan J, Zhang Q, Du M, Zhang P, Nevalainen M, Kohli M, Shenoy NK, Meng H, You M, Wang L.

Mol Cancer. 2016 Nov 10;15(1):70.


Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.

Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH.

Cancer Res. 2005 Aug 1;65(15):6934-42. Erratum in: Cancer Res. 2005 Dec 1;65(23):11228.


Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.

Kato T, Mizutani K, Kameyama K, Kawakami K, Fujita Y, Nakane K, Kanimoto Y, Ehara H, Ito H, Seishima M, Deguchi T, Ito M.

Urol Oncol. 2015 Sep;33(9):385.e15-20. doi: 10.1016/j.urolonc.2015.04.019. Epub 2015 May 28.


Supplemental Content

Support Center